Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting 2023-09-06 20:00
Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors 2023-08-07 23:14
Gracell Biotechnologies Presents Updated Data of Deep and Durable Responses for FasTCAR-T GC012F in Relapsed/Refractory Multiple Myeloma at 2023 ASCO Annual Meeting 2023-06-04 02:15
Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE) 2023-05-15 19:00
Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in RRMM and B-NHL and Donor-Derived CAR-T GC007g in B-ALL at EHA2023 Congress 2023-05-12 05:28
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F at 2023 ASCO Annual Meeting 2023-04-26 22:15
Gracell Biotechnologies to Participate in Oppenheimer 33rd Annual Healthcare Conference 2023-02-28 21:00
Gracell Biotechnologies to Report Fourth Quarter 2022 Financials on Monday, March 13, 2023 2023-02-27 21:00
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma 2023-02-13 20:30
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma 2023-02-03 20:30
Gracell Biotechnologies Presents Clinical Data for FasTCAR-T GC012F for High Risk, Newly Diagnosed Multiple Myeloma Demonstrating 100% Overall Response Rate 2022-12-11 07:15
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences 2022-11-23 21:00
Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award 2022-11-16 21:00
Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition 2022-11-03 21:10
Gracell Biotechnologies to Report Third Quarter 2022 Financials on Monday, November 14, 2022 2022-10-31 21:00
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences 2022-10-24 21:00
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia 2022-10-17 20:05
Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences 2022-09-14 20:30
Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences 2022-08-29 21:00
Gracell Biotechnologies to Report Second Quarter 2022 Financial on Monday, August 15, 2022 2022-08-02 21:00
1 2 3